CN113893345A - 247 compounds and their use in combating infection by new coronaviruses - Google Patents

247 compounds and their use in combating infection by new coronaviruses Download PDF

Info

Publication number
CN113893345A
CN113893345A CN202010577020.0A CN202010577020A CN113893345A CN 113893345 A CN113893345 A CN 113893345A CN 202010577020 A CN202010577020 A CN 202010577020A CN 113893345 A CN113893345 A CN 113893345A
Authority
CN
China
Prior art keywords
coronavirus
active ingredient
cov
sars
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010577020.0A
Other languages
Chinese (zh)
Inventor
李佳
赵强
蒋华良
苏明波
张文茹
程曦
臧奕
郑明月
蒋映艳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Priority to CN202010577020.0A priority Critical patent/CN113893345A/en
Publication of CN113893345A publication Critical patent/CN113893345A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to application of 247 effective components of compounds in resisting coronavirus. In particular, the invention relates to 247 compounds shown in table 1 or compositions thereof as inhibitors of novel coronavirus PLproAn inhibitor of protein activity; and/or (b) the treatment and/or prevention, alleviation of related diseases caused by novel coronavirus infections.

Description

247 compounds and their use in combating infection by new coronaviruses
Technical Field
The invention relates to the field of medicines, in particular to application of 247 effective components of compounds in resisting virus infection, especially application in resisting coronavirus infection.
Background
In acute infectious diseases, most of the infectious diseases are viral infectious diseases, the incidence rate of the viral infectious diseases is high, and the death rate is high. Because the detection and diagnosis means are limited, the outbreak of new epidemic caused by new viruses often has the characteristics of paroxysmal, random, unpredictable and the like, once the outbreak occurs, if no effective prevention and treatment means exists, the large-scale epidemic is very easy to cause, and the health and life safety of people is seriously threatened.
Coronaviruses (Coronaviruses) are single-stranded positive-strand RNA viruses belonging to the order Nidovirales (Nidovirales) Coronaviridae (Coronaviridae) orthocoronaviridae (orthocoronaviridae) and can infect various species such as humans, bats, pigs, mice, cows, horses, goats, monkeys, etc. There are 6 known human-infecting coronaviruses (HCoV), including middle east respiratory syndrome-associated coronavirus (MERSR-CoV) and severe acute respiratory syndrome-associated coronavirus (SARSr-CoV).
The novel coronavirus 2019-nCoV (SARS-CoV-2) is the 7 th coronavirus infecting human, and can cause severe pneumonia. The 2019-nCoV virus transmission path is not completely mastered, is known to be transmitted by droplets and contact, and has the possibility of infection of people and medical staff, certain community transmission risk and virus variation. There is currently no specific preventive or therapeutic approach for diseases caused by the novel coronavirus.
2019-nCoV coronavirus belongs to coronavirus of coronavirus family, and is single-chain positive virus with envelopeA sense RNA virus. Similar to other known coronaviruses, the 2019-nCoV coronaviruses also complete the propagation of the offspring viruses through the processes of adsorption, penetration, uncoating, biosynthesis, assembly and release of the offspring viruses and the like. 2019-nCoV coronavirus infects host cells, the spike glycoprotein initiated on the surface of a virus envelope is combined with a receptor on the surface of the host cells, then membrane fusion occurs, the virus enters the host cells, the virus genetic material single-chain positive-sense RNA is released under the action of organelles such as cell lysosome, and the like, and the polyprotein is generated by translation under the action of protein synthesis elements such as mitochondria, ribosome and the like of the host cells and necessary raw materials, and then two essential cysteine proteases of the 2019-nCoV coronavirus are obtained: papain (PL)pro) And 3C-like protease (3C-like protease,3 CL)pro) Cleavage at specific sites processes the polyprotein precursors, producing a number of non-structural proteins that are important to the viral life cycle. Under the action of these nonstructural proteins, the viral RNA replicates the daughter viral nucleic acid material and translates to a large amount of the desired structural proteins, completing assembly and release of the daughter virus. Any link or key enzyme of the life cycle of 2019-nCoV coronavirus infected cells can be used as a research target of antiviral drugs, such as cysteine protease PL for hydrolyzing and cutting polyprotein precursorsproAnd 3CLproRNA polymerase responsible for completing replication of progeny viral genetic material, and the like.
At present, no specific vaccine or antiviral drug exists for severe pneumonia diseases caused by SARS-CoV-2 coronavirus. These infectious diseases seriously affect the life health of people, and the research and development of antiviral drugs with good effect is urgent. Aiming at SARS-CoV-2 coronavirus, a low-toxicity and high-efficiency antiviral drug is developed to meet the clinical requirements of SARS-CoV-2 coronavirus infected patients at home and abroad, and has great social significance.
In view of the above, there is an urgent need in the art to develop inhibitors against SARS-CoV-2 coronavirus for the treatment of pneumonia caused by infection with the novel coronavirus.
Disclosure of Invention
The object of the present invention is to provideEffective inhibition of novel coronavirus PLproA medicinal active component of the protein and a new application thereof in diseases such as pneumonia caused by novel coronavirus infection.
In a first aspect of the present invention, there is provided a use of an active ingredient or a formulation containing the active ingredient, wherein the active ingredient is any one compound or combination thereof selected from the 247 compounds in table 1 (i.e. any one compound or combination thereof numbered 1 to 247 in table 1), or a pharmaceutically acceptable salt or composition thereof:
and, the preparation of the active ingredient or a pharmaceutical composition containing the active ingredient is used for preparing (a) a formulation for inhibiting coronavirus PLproInhibitors of protein active ingredients; and/or (b) a medicament for the treatment and/or prevention, amelioration of a related disease caused by a coronavirus infection.
In another preferred embodiment, the preparation of the active ingredient or a pharmaceutical composition containing the active ingredient is used for preparing (a) inhibiting novel coronavirus (SARS-CoV-2) PLproInhibitors of protein active ingredients; and/or (b) a medicament for the treatment and/or prevention, amelioration of the associated diseases caused by the novel coronavirus infection.
In another preferred embodiment, the coronavirus is a human-infecting coronavirus selected from the group consisting of: SARS-CoV (Severe acute respiratory syndrome coronavirus), 2019 novel coronavirus (2019-nCoV or SARS-CoV-2), MERS-CoV (Middle East respiratory syndrome coronavirus), or common cold-causing coronavirus; the common cold-causing coronavirus is preferably Human coronavirus OC43(Human coronavirus OC43), Human coronavirus 229E (Human coronavirus 229E), Human coronavirus NL63(Human coronavirus NL63), and Human coronavirus HKUL (Human coronavirus HKUL).
In another preferred embodiment, the coronavirus-induced related disease is selected from the group consisting of: cold symptoms caused by human coronavirus, high risk symptom infection, respiratory infection, pneumonia and its complications, novel coronavirus pneumonia caused by SARS-CoV-2 (Corona Virus Disease 2019, COVID-19), or their combination.
In another preferred example, the related disease caused by the 2019 novel coronavirus infection is selected from the group consisting of: respiratory infections, pneumonia and its complications, or combinations thereof.
In another preferred embodiment, the active ingredient is selected from the group consisting of: CD0945-G005, CD0946-B009, CD3226-D010, CD3531-C011 or pharmaceutical compositions thereof.
In another preferred embodiment, the pharmaceutical composition containing the active ingredient may also contain other antiviral agents.
In another preferred embodiment, the medicament further comprises an additional component selected from the group consisting of: anti-lung injury drugs, anti-inflammatory drugs or drugs with immunomodulatory effects.
In another preferred embodiment, the medicament further comprises an additional component selected from the group consisting of: zinc (Zinc), Fingolimod (Fingolimod), vitamin c (vitamin c), Olmesartan Medoxomil (Olmesartan Medoxomil), valsartan (valsartan), Losartan (Losartan), Thalidomide (thiaidomide), glycyrrhizic acid (glycyrrhetic acid), Artemisinin (Artemisinin), dihydroartemisinin (dihydroartemesinin), Artesunate (Artesunate), Artemisone (Artemisone), Azithromycin (Azithromycin), Escin (Escin), Naproxen (Naproxen), or combinations thereof.
In another preferred embodiment, the composition or medicament comprises: oral and non-oral formulations.
In another preferred embodiment, the formulation comprises: powder, granule, capsule, injection, tincture, oral liquid, tablet, buccal tablet, or dripping pill.
In a second aspect of the present invention, there is provided a pharmaceutical composition comprising:
(a1) a first active ingredient selected from the group consisting of: 247 compounds of table 1 or a pharmaceutically acceptable salt or composition thereof;
(a2) optionally a second active ingredient which is an antiviral drug selected from the group consisting of: interferons, RNA-dependent RNA polymerase inhibitors (e.g., Remdesivir (Rudexilevir or GS-5734), Favipiravir (favipiravir), Galidesivir, GS-441524); lopinavir (Lopinavir), Ritonavir (Ritonavir), Nelfinavir (Nelfinavir); chloroquine (Chloroquine, Sigma-C6628), hydroxychloroquine (hydroxychloroquine), cyclosporine (cyclosporine), colimycin (carromycin), baicalin (baicain), baicalein (baicalein), Naphthoquine (napthoquine), Ciclesonide (Ciclesonide), Ribavirin (Ribavirin), Penciclovir (Penciclovir), Leflunomide (Leflunomide), Teriflunomide (Teriflunomide), naftifimide (temulomide), nafamostat (nafamostat), nitate (nitazoxanide), Darunavir (Darunavir), Arbidol (Arbidol), Camostat (Camostat), Niclosamide (nicamide), bartinib (barnitinib), rurunavir (raltinib), Saquinavir (Saquinavir), sinavir (quinavir), or a pharmaceutically acceptable salt thereof;
and/or said second active ingredient is selected from the group consisting of: zinc (Zinc), Fingolimod (Fingolimod), vitamin c (vitamin c), Olmesartan Medoxomil (Olmesartan Medoxomil), valsartan (valsartan), Losartan (Losartan), Thalidomide (Thalidomide), glycyrrhizic acid (glycyrrhizic acid), Artemisinin (Artemisinin), dihydroartemisinin (dihydroartemisinin), Artesunate (Artesunate), Artemisone (artemosone), Azithromycin (Azithromycin), Escin (Escin), Naproxen (Naproxen), or combinations thereof;
and (b) a pharmaceutically acceptable carrier.
In another preferred embodiment, the second active ingredient is selected from the group consisting of: (Y1) RNA replicase inhibitors (e.g., Remdesivir (redevir or GS-5734)); (Y2) Lopinavir (Lopinavir); (Y3) Ritonavir (Ritonavir); (Y4) favipiravir; (Y5) Chloroquine (Chloroquine, Sigma-C6628), hydroxychloroquine (hydroxychloroquine), or a pharmaceutically acceptable salt thereof (e.g., Chloroquine phosphate), (Y6) Nelfinavir (Nelfinavir); (Y7) any combination of the above Y1 to Y6.
In another preferred embodiment, the pharmaceutical composition is used for inhibiting coronavirus PLproAnd (3) protein activity.
At another placeIn a preferred embodiment, the pharmaceutical composition is used for inhibiting 2019 novel coronavirus (2019-nCoV)/(SARS-CoV-2) PLproAnd (3) protein activity.
In a third aspect of the invention, there is provided the use of a pharmaceutical composition according to the second aspect for the preparation of a medicament for (a) inhibiting a coronavirus; and/or (b) a medicament for the treatment and/or prevention, amelioration of a related disease caused by a coronavirus infection.
In another preferred example, the inhibitor is used for preparing (a) inhibiting 2019 novel coronavirus (SARS-CoV-2)/(2019-nCoV) PLproAn inhibitor of protein activity; and/or (b) a medicament for treating and/or preventing, and/or alleviating related diseases caused by 2019 novel coronavirus (SARS-CoV-2) infection.
In a fourth aspect of the present invention, there is provided a method for inhibiting a novel coronavirus PLproA method of producing a protein comprising the steps of:
mixing a first active ingredient or a preparation containing the first active ingredient with PL of coronavirus (SARS-CoV-2)proProtein contact, inhibition of said coronavirus PLproThe activity of the protein; or
Contacting a first active ingredient or a formulation comprising said first active ingredient with a coronavirus (SARS-CoV-2) to inhibit said coronavirus PLproActivity of the protein, thereby inhibiting replication of the coronavirus;
wherein the first active ingredient is selected from the group consisting of the compounds of table 1 or pharmaceutically acceptable salts thereof or combinations thereof.
In another preferred embodiment, the first active ingredient is selected from the group consisting of: CD0945-G005, CD0946-B009, CD3226-D010, CD3531-C011, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
In another preferred embodiment, the first active ingredient is a pharmaceutical active ingredient of the following group:
in another preferred embodiment, the method is an in vitro method.
In another preferred embodiment, the method is non-therapeutic and non-diagnostic.
It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments. Not to be reiterated herein, but to the extent of space.
Drawings
None.
Detailed Description
The present inventors have conducted extensive and intensive studies and, as a result of extensive screening, have unexpectedly developed 247 pharmaceutically active ingredients effective in inhibiting novel coronavirus PL for the first timeproA protein. Experiments have shown that the active ingredients (represented by CD0945-G005, CD0946-B009, CD3226-D010, and CD 3531-C011) of the present invention can efficiently inhibit the novel coronavirus PLproThe activity of the protein. The present invention has been completed based on this finding.
Specifically, the present invention discloses pharmaceutically active ingredients selected from the group consisting of: use of CD0945-G005 against novel coronaviruses. The pharmaceutical active ingredient of the present invention has excellent inhibitory activity against novel coronavirus PLproThe protein activity can inhibit the replication of the novel coronavirus, and has good clinical application prospect.
Term(s) for
As used herein, "active ingredient of the present invention", "inhibiting novel coronavirus PL of the present inventionproActive ingredients of protein "," 247 compounds "," 247 active ingredients ", and" active ingredients of the present invention "are used interchangeably and mean having excellent inhibitory activity against coronavirus PLproAny active ingredient for protein activity, including any one of the 247 compounds selected from table 1 and combinations thereof.
As used herein, "formulation of the present invention" refers to a formulation containing an active ingredient of the present invention.
As used herein, the term "comprising" or variations thereof, such as "comprises" or "comprising," etc., are understood to imply the inclusion of stated elements or components but not the exclusion of any other elements or components.
As used herein, the terms "novel coronavirus", "2019-nCov" or "SARS-CoV-2" are used interchangeably, the 2019 novel coronavirus being the 7 th coronavirus known to infect humans and causing new coronary pneumonia (COVID-19), one of the serious infectious diseases threatening global human health.
Coronavirus (coronavirus)
Coronaviruses (CoV) belong to the family of the Nidovirales (Nidovirales) Coronaviridae (Coronaviridae), a enveloped positive-strand RNA virus, a subfamily of which contains four genera, alpha, beta, delta and gamma.
Among the currently known human-infecting coronaviruses, HCoV-229E and HCoV-NL63 belong to the genus alpha, and HCoV-OC43, SARS-CoV, HCoV-HKU1, MERS-CoV and SARS-CoV-2 are all the genus beta. SARS-CoV-2 is also known as 2019-nCov.
Highly pathogenic coronavirus "SARS-CoV" and "middle east respiratory syndrome" MERS-CoV both belong to the genus beta coronavirus. The novel coronavirus (SARS-CoV-2) has about 80% similarity to SARS-CoV and 40% similarity to MERS-CoV, and also belongs to the genus beta coronavirus.
The genome of the virus is a single-strand positive-strand RNA, is one of RNA viruses with the largest genome, and codes of the RNA viruses comprise replicase and PLproProteins, envelope proteins, nucleocapsid proteins, and the like. In the initial stage of viral replication, the genome is translated into two peptide chains of up to several thousand amino acids, the precursor Polyprotein (Polyprotein), which is subsequently cleaved by proteases to produce nonstructural proteins (e.g., RNA polymerase and helicase) and structural proteins (e.g., PL)proProtein) and accessory proteins.
Active Compounds and active ingredients of the invention
In the present invention, effective inhibition of coronavirus PL is providedproActive ingredient of protein activity. The active ingredient is selected from the compounds of table 1 shown below, or pharmaceutically acceptable salts thereof, or combinations thereof.
TABLE 1247 Compounds
Figure BDA0002551380300000061
Figure BDA0002551380300000071
Figure BDA0002551380300000081
Figure BDA0002551380300000091
Figure BDA0002551380300000101
Figure BDA0002551380300000111
Figure BDA0002551380300000121
Figure BDA0002551380300000131
Figure BDA0002551380300000141
Figure BDA0002551380300000151
Figure BDA0002551380300000161
Figure BDA0002551380300000171
Figure BDA0002551380300000181
Figure BDA0002551380300000191
Figure BDA0002551380300000201
Figure BDA0002551380300000211
Figure BDA0002551380300000221
Experiments show that the active ingredients of the invention can effectively inhibit PL of novel coronavirusproProtein activity, thereby preventing, treating and/or ameliorating diseases associated with the novel coronavirus.
As used herein, "the active ingredient of the present invention", "the active compound of the present invention inhibiting coronavirus replication" are used interchangeably and refer to a compound having an excellent activity of inhibiting coronavirus replication.
It is to be understood that the active ingredients of the present invention include any one of the compounds of table 1 and combinations thereof.
Or a pharmaceutically acceptable salt, enantiomer, diastereomer or racemate thereof, or a prodrug thereof. It is to be understood that the active ingredients of the present invention also include crystalline forms of the active compounds of the present invention, amorphous compounds, and deuterated compounds, among others.
The "pharmaceutically acceptable salts" are conventional non-toxic salts formed by reacting the active compounds of the present invention with inorganic or organic acids. For example, conventional non-toxic salts can be prepared by reacting the active compounds of the present invention with inorganic acids including hydrochloric, hydrobromic, sulfuric, nitric, sulfamic, phosphoric, and the like, or organic acids including citric, tartaric, lactic, pyruvic, acetic, benzenesulfonic, p-toluenesulfonic, methanesulfonic, naphthalenesulfonic, ethanesulfonic, naphthalenedisulfonic, maleic, malic, malonic, fumaric, succinic, propionic, oxalic, trifluoroacetic, stearic, pamoic, hydroxymaleic, phenylacetic, benzoic, salicylic, glutamic, ascorbic, p-aminobenzenesulfonic, 2-acetoxybenzoic, isethionic, and the like; or sodium, zinc, potassium, calcium, aluminum or ammonium salts of the active compounds of the invention formed with propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, aspartic acid or glutamic acid in an ester and then with an inorganic base; or the corresponding inorganic acid salt formed by the active compound of the invention and lysine, arginine and ornithine and then hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid or phosphoric acid, or the corresponding organic acid salt formed by the active compound of the invention and formic acid, acetic acid, picric acid, methanesulfonic acid or ethanesulfonic acid; or a sodium salt, a zinc salt, a potassium salt, a calcium salt, an aluminum salt or an ammonium salt of a carboxyl group/phenolic hydroxyl group in the molecule of the active compound of the present invention and an inorganic base.
Furthermore, the active ingredients of the invention are particularly suitable for use in combination with other anti-coronavirus drugs. Representative other anti-coronavirus drugs include (but are not limited to): interferons, RNA-dependent RNA polymerase inhibitors (e.g., Remdesivir (Rudexilevir or GS-5734), Favipiravir (favipiravir), Galidesvir, GS-441524); 3CL protease inhibitors (e.g., GC-376), Lopinavir (Lopinavir), Ritonavir (Ritonavir), Nelfinavir (Nelfinavir); chloroquine (Chloroquine, Sigma-C6628), hydroxychloroquine, cyclosporine (cyclosporine), clarithromycin (carrlomycin), baicalin (baicain), baicalein (baicalein), Naphthoquine (napheroquine), Ciclesonide (Ciclesonide), Ribavirin (Ribavirin), Penciclovir (Penciclovir), Leflunomide (Leflunomide), Teriflunomide (Teriflunomide), nafamostat (nafamostat), nitazoxanide (nitazoxanide), Darunavir (Darunavir), Arbidol (Arbidol), Camostat (Camostat), Niclosamide (nicamide), bartinib (baricitinib), cricotinib (rulitinib), Dasatinib (Dasatinib), saquinar (quinacrid), quinavir (bevir), or a pharmaceutically acceptable salt thereof. The interferon comprises one or more of interferon alpha-2 a, interferon alpha-2 b, interferon alpha-n 1, interferon alpha-n 3, interferon beta-1 a and interferon beta-1 b.
In addition, since SARS-CoV-2 infection can cause acute lung injury, inflammatory response and even cytokine storm, the active ingredients of the present invention are also particularly suitable for use in combination with drugs having an effect of ameliorating acute lung injury, an anti-inflammatory effect or an immune modulating effect. Representative drugs include, but are not limited to, Zinc (Zinc), Fingolimod (Fingolimod), vitamin c (vitamin c), Olmesartan Medoxomil (olmestanan Medoxomil), valsartan (valsartan), Losartan (Losartan), Thalidomide (Thalidomide), glycyrrhizic acid (glycyrrhetic acid), Artemisinin (artemizin), dihydroartemisinin (dihydroartesunine), Artesunate (Artesunate), Artemisone (Artemisone), Azithromycin (Azithromycin), Escin (Escin), Naproxen (Naproxen).
Preferably, the active ingredient of the invention is combined with artemisinin drugs (one or more of artemisinin, dihydroartemisinin, artesunate and arteannuin). A large number of researches show that the artemisinin drugs have multiple anti-inflammatory and immunoregulatory mechanisms, realize anti-inflammatory and immunoregulatory functions by inhibiting T cell proliferation and activation, inhibiting B cell activation and antibody generation, increasing regulatory T cells and reducing release of inflammatory cytokines, and are expected to relieve immune injury symptoms caused by SARS-CoV-2 infection.
Preferably, the active ingredient of the invention is combined with artemisinin drugs (one or more of artemisinin, dihydroartemisinin, artesunate and arteannuin) and azithromycin.
The active ingredient of the invention can inhibit the infection activity of novel coronavirus such as SARS-CoV-2. Therefore, when the active ingredient of the present invention is therapeutically administered or administered, the infection with the novel coronavirus of 2019 (SARS-CoV-2) can be inhibited, thereby achieving an antiviral effect.
Pharmaceutical composition and application
The invention also provides application of the active compound for inhibiting the replication of the coronavirus, or one or more mixtures of pharmaceutically acceptable salts or prodrugs thereof as an active ingredient in preparing a medicament for treating and/or preventing and relieving diseases related to respiratory tract infection, pneumonia and the like caused by infection of the coronavirus such as 2019 novel coronavirus.
The pharmaceutical composition provided by the present invention preferably contains 0.001-99 wt% of active ingredient, preferably 0.1-90 wt% or 1-50 wt% of active compound of the present invention as active ingredient, the rest being pharmaceutically acceptable carrier, diluent or solution or salt solution.
If necessary, one or more pharmaceutically acceptable carriers can be added into the medicine. The carrier comprises diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption enhancers, surfactants, adsorption carriers, lubricants and the like which are conventional in the pharmaceutical field.
The compounds and pharmaceutical compositions provided herein may be in a variety of forms such as tablets, capsules, powders, syrups, solutions, suspensions and aerosols, and the like, and may be presented in a suitable solid or liquid carrier or diluent and in a suitable sterile vehicle for injection or instillation.
Various dosage forms of the pharmaceutical composition of the present invention can be prepared according to conventional preparation methods in the pharmaceutical field. The unit dose of the formulation generally comprises 0.05 to 400mg of active compound according to the invention, preferably 1 to 500mg of active compound according to the invention.
The compounds and pharmaceutical compositions of the present invention may be administered to mammals in clinical use, including humans and animals, by oral, nasal, dermal, pulmonary or gastrointestinal routes of administration. Most preferably oral. Most preferably, the daily dose is 0.01-400mg/kg body weight, and is administered once or in portions of 0.01-200mg/kg body weight. Regardless of the method of administration, the optimal dosage for an individual will depend on the particular treatment. Usually starting with a small dose and gradually increasing the dose until the most suitable dose is found.
The drug or inhibitor of the present invention can be administered by a variety of different means, e.g., by injection, spray, nasal drop, eye drop, osmotic, absorption, physical or chemical mediated methods, into the body such as muscle, intradermal, subcutaneous, intravenous, mucosal tissue; or mixed with other materials or encapsulated and introduced into body.
Typically, the active ingredient of the invention or a pharmaceutical composition containing it is administered in unit dosage form, either enterally or parenterally, such as orally, intravenously, intramuscularly, subcutaneously, nasally, oromucosally, ocularly, pulmonary and respiratory, dermally, vaginally, rectally, and the like.
The dosage form for administration may be a liquid dosage form, a solid dosage form, or a semi-solid dosage form. The liquid dosage forms can be solution (including true solution and colloidal solution), emulsion (including o/w type, w/o type and multiple emulsion), suspension, injection (including water injection, powder injection and infusion), eye drop, nose drop, lotion, liniment, etc.; the solid dosage form can be tablet (including common tablet, enteric coated tablet, buccal tablet, dispersible tablet, chewable tablet, effervescent tablet, orally disintegrating tablet), capsule (including hard capsule, soft capsule, and enteric coated capsule), granule, powder, pellet, dripping pill, suppository, pellicle, patch, aerosol (powder), spray, etc.; semisolid dosage forms can be ointments, gels, pastes, and the like.
The active ingredients of the invention can be prepared into common preparations, sustained release preparations, controlled release preparations, targeting preparations and various particle delivery systems.
In order to formulate the active ingredients of the present invention into tablets, a wide variety of excipients known in the art can be used, including diluents, binders, wetting agents, disintegrants, lubricants, glidants. The diluent can be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.; the wetting agent can be water, ethanol, isopropanol, etc.; the adhesive can be starch slurry, dextrin, syrup, Mel, glucose solution, microcrystalline cellulose, acacia slurry, gelatin slurry, sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, ethyl cellulose, acrylic resin, carbomer, polyvinylpyrrolidone, polyethylene glycol, etc.; the disintegrant can be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, crosslinked polyvinylpyrrolidone, crosslinked sodium carboxymethylcellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitol fatty acid ester, sodium dodecyl sulfate, etc.; the lubricant and glidant may be talc, silica, stearate, tartaric acid, liquid paraffin, polyethylene glycol, etc.
The tablets may be further formulated into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer and multi-layer tablets.
To prepare the administration units into capsules, the active ingredients of the invention can be mixed with diluents, glidants and the mixture placed directly into hard or soft capsules. Or mixing the effective components with diluent, binder, and disintegrating agent, making into granule or pellet, and placing into hard capsule or soft capsule. The diluents, binders, wetting agents, disintegrants, glidants used to prepare the tablets of the invention may also be used to prepare the capsules of the invention.
In order to prepare the active ingredients of the invention into injection, water, ethanol, isopropanol, propylene glycol or the mixture of the water, the ethanol, the isopropanol and the propylene glycol can be used as a solvent, and a proper amount of solubilizer, cosolvent, pH regulator and osmotic pressure regulator which are commonly used in the field can be added. The solubilizer or cosolvent can be poloxamer, lecithin, hydroxypropyl-beta-cyclodextrin, etc.; the pH regulator can be phosphate, acetate, hydrochloric acid, sodium hydroxide, etc.; the osmotic pressure regulator can be sodium chloride, mannitol, glucose, phosphate, acetate, etc. For example, mannitol and glucose can be added as proppant for preparing lyophilized powder for injection.
In addition, colorants, preservatives, flavors, or other additives may also be added to the pharmaceutical preparation, if desired.
The active ingredient or composition of the present invention can be taken alone or in combination with other therapeutic or symptomatic agents.
When the active ingredient of the present invention acts synergistically with other therapeutic agents, its dosage should be adjusted according to the actual circumstances.
The main advantages of the invention include:
(a) the active compound of the invention can effectively inhibit SARS-CoV-2 (novel coronavirus) and has obvious antiviral effect. Wherein WNN3369-C011 inhibits the IC of SARS-CoV50A value of about 0.18. mu.M; IC of NCRW0370-F002 for inhibiting SARS-CoV-250The value was only 0.28. mu.M; IC of RUS0093-G006 for inhibiting SARS-CoV-250A value of about 0.32. mu.M; IC for WNN3768-D008 inhibiting SARS-CoV-250A value of about 0.5. mu.M; IC of PC0003-B003 for inhibiting SARS-CoV-250The value was about 0.51. mu.M.
(b) The active compound of the invention has low toxic and side effects and good drug property. The active ingredients of the invention are provided with good medical prospect in the field of anti-neocoronary pneumonia. Wherein, when representing compound CD0945-G005 inhibits the activity of SARS-CoV by 94.26%, the cytotoxicity is only 6.03%.
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are only for illustrating the present invention and are not intended to limit the scope of the present invention. The experimental procedures, without specific conditions being noted in the following examples, are generally performed according to conventional conditions, such as Sambrook et al, molecular cloning: the conditions described in the Laboratory Manual (New York: Cold Spring Harbor Laboratory Press,1989), or according to the manufacturer's recommendations. Unless otherwise indicated, percentages and parts are percentages and parts by weight.
Example 1 anti-SARS-CoV-2 Virus surface PLproprotein-Activity assay
The experimental apparatus used in this example: microplate reader envision tm (PerkinElmer, USA), experimental materials: recombinant SARS-CoV 2PLproFull-length protein using Escherichia coliExpressing and purifying the expression system to obtain; the polypeptide substrate Z-RLRGG-AMC was synthesized by Gill Biochemical company.
The test principle is as follows: based on SARS-CoV-2PLproThe protein is a basic characteristic of proteolytic enzyme, and a screening system for detecting the activity of SARS-CoV-2PLpro protein by a fluorescence method is established. SARS-CoV-2PLproThe protein can specifically recognize and cut the diglycine polypeptide, the activity detection can adopt fluorescent polypeptide as a substrate, and the activity of the proteolytic enzyme is reflected by detecting the generation of a fluorescent signal.
Specifically, SARS-CoV 2PLproIs a proteolytic enzyme, which can specifically recognize and cut the diglycine polypeptide, and the activity detection can adopt fluorescent polypeptide Z-RLRGG-AMC as a substrate when SARS-CoV 2PLproWhen protease activity is exerted, the polypeptide chain is cleaved to release fluorescent AMC, so that AMC can release 460nm emitted light under 355nm excitation light, and SARS-CoV 2PL is reacted by detecting generation of 460nm fluorescence signalproActivity of (2).
The test method comprises the following steps: the total volume of the test is 50 mu L, and the specific reaction system is as follows: 20mM Tris pH8.0, 0.01% Tween20,0.5mM DTT,40nM PLpro50 μ M substrate polypeptide and different concentration gradients of compounds, while a DMSO only solvent control was set up.
The samples were dissolved in DMSO and stored at low temperature, and the concentration of DMSO in the final system was controlled within a range that did not affect the detection activity. The samples are tested for activity under a single concentration of the primary screen, e.g., 10. mu.g/mL. For samples that exhibit activity under certain conditions, e.g., an Inhibition% Inhibition greater than 50, the activity dose dependence, i.e., IC, is tested50Values, obtained by non-linear fitting of sample concentrations by sample activity, were calculated as Graphpad Prism 5 using software, as model for fitting was sigmoidal dose-response (variable slope), and for most inhibitor screening models, the bottom and top of the fitted curve were set at 0 and 100.
The experimental results are as follows: the activity of 247 compounds for inhibiting SARS-Cov-2 was determined as shown in Table 2.
Table 2: 247 Compounds for inhibiting SARS-Cov-2PLproActivity of proteins
Figure BDA0002551380300000271
Figure BDA0002551380300000281
Figure BDA0002551380300000291
EXAMPLE 2 anti-SARS-CoV-2 Virus cytotoxicity assay
The test principle is as follows: the cell infected with SARS-CoV-2 virus is used as virus host cell, and the test sample has SARS-CoV-2 copying blocking activity, which can reflect the antiviral activity of SARS-CoV-2 infection key target. The detection index is the activity level of a reporter gene on the pseudovirus genome.
The test method comprises the following steps:
inoculating virus-infected cells to 96-well culture plate one day in advance, setting active plate and cytotoxic plate respectively, placing at 37 deg.C and 5% CO2And (5) culturing. The activity assay plate and the cytotoxicity assay plate are added with samples with different dilution concentrations and SARS-CoV-2 pseudovirus suspension according to the same sample adding mode, and a virus control, a cell control and a sample control are set. After further 3 days of culture, the cytotoxic plates were assayed for cell viability using the MTT method. And (3) sucking the culture solution by using an active plate, adding 100 mu L of cell lysate into each hole, performing shake lysis for 5 minutes, adding 100 mu L of Luciferase reaction detection solution into each hole, performing shake incubation for 5 minutes, and determining the chemiluminescence value.
The evaluation method comprises the following steps:
cytotoxicity (MTT method): by comparing the OD values of the virus control, cell control and sample control, the viability of the cells was calculated and further the cytotoxic effect of the samples was calculated.
The experimental results are as follows:
the data for determining the anti-SARS-CoV-2 virus activity and cytotoxicity of 247 compounds are shown in Table 3:
TABLE 3247 anti-SARS-CoV-2 virus activity and cytotoxicity of compounds
Figure BDA0002551380300000301
Figure BDA0002551380300000311
Figure BDA0002551380300000321
Figure BDA0002551380300000331
As can be seen from Table 3, the compounds of the present invention not only effectively inhibit SARS-CoV-2 virus activity, but also ensure low cytotoxicity. In particular, the representative compound CD0945-G005 exhibited 94.26% antiviral activity, and the cytotoxicity was only 6.03%. Therefore, the preferable compound of the invention can be widely applied to clinic and has good medicinal prospect.
Discussion of the related Art
1. Coronavirus is an RNA virus whose proliferation depends on the regeneration of maternal RNA by RNA-dependent RNA polymerase (RdRp), where SARS-Cov-2 is the cause of new coronary pneumonia, SARS-Cov-2PLproThe protein is one of key proteins of which 2019-nCoV key protein RdRp becomes an active form, and SARS-Cov-2PLproHas been considered as one of the drug targets for treating coronary pneumonia. The compounds in Table 2 of the present invention showed very excellent SARS-Cov-2PLproInhibiting the activity. The compounds of the invention are directed against SARS-Cov-2PLproIC of50The value can be as low as 0.18 +/-0.03 mu M, which indicates that the compound has the capability of inhibiting the proliferation of SARS-Cov-2, thereby achieving the purpose of treating the new coronary pneumonia.
2. The coronavirus is taken as a virus subspecies, has relatively similar pathogenesis and whole life cycle, and mainly comprises SARS-CoV (Severe acute respiratory syndrome coronavirus), 2019 novel coronavirus (2019-nCoV or SARS-CoV-2), MERS-CoV (Middle East respiratory syndrome coronavirus) or common cold coronavirus; the common cold-causing coronavirus is preferably Human coronavirus OC43(Human coronavirus OC43), Human coronavirus 229E (Human coronavirus 229E), Human coronavirus NL63(Human coronavirus NL63), Human coronavirus HKUl (Human coronavirus HKUl) and the like, different coronaviruses have papain-like PLpro with high homology, so that the novel compound discovered by SARS-CoV-2PLpro possibly has the function of inhibiting other coronaviruses, and therefore the compound also provides a novel solution for other coronaviruses.
All documents referred to herein are incorporated by reference into this application as if each were individually incorporated by reference. Furthermore, it should be understood that various changes and modifications of the present invention can be made by those skilled in the art after reading the above teachings of the present invention, and these equivalents also fall within the scope of the present invention as defined by the appended claims.

Claims (10)

1. Use of an active ingredient or a formulation containing said active ingredient, wherein said active ingredient is: any one compound or combination thereof or pharmaceutically acceptable salt thereof, or combination thereof, selected from the 247 compounds of table 1;
and, the preparation of the active ingredient or a pharmaceutical composition containing the active ingredient is used for preparing (a) a formulation for inhibiting coronavirus PLproInhibitors of protein active ingredients; and/or (b) a medicament for the treatment and/or prevention, amelioration of a related disease caused by a coronavirus infection.
2. The use of claim 1, wherein the coronavirus is a human-infecting coronavirus selected from the group consisting of: SARS-CoV (Severe acute respiratory syndrome coronavirus), 2019 novel coronavirus (2019-nCoV or SARS-CoV-2), MERS-CoV (Middle East respiratory syndrome coronavirus), or common cold-causing coronavirus; the common cold-causing coronavirus is preferably Human coronavirus OC43(Human coronavirus OC43), Human coronavirus 229E (Human coronavirus 229E), Human coronavirus NL63(Human coronavirus NL63), and Human coronavirus HKUL (Human coronavirus HKUL).
3. The use of claim 1, wherein the disease associated with coronavirus is selected from the group consisting of: cold symptoms caused by human coronavirus, high risk symptom infection, respiratory infection, pneumonia and its complications, novel coronavirus pneumonia caused by SARS-CoV-2 (Corona Virus Disease 2019, COVID-19), or their combination.
4. The use according to claim 1, wherein the active ingredient is selected from the group of pharmaceutically active ingredients consisting of: CD0945-G005, CD0946-B009, CD3226-D010, CD3531-C011 or pharmaceutical compositions thereof.
5. The use of claim 1, wherein said composition or medicament comprises: oral and non-oral formulations.
6. A pharmaceutical composition, comprising:
(a1) a first active ingredient selected from the group consisting of: 247 compounds of table 1 or a pharmaceutically acceptable salt or composition thereof;
(a2) optionally a second active ingredient which is an antiviral drug selected from the group consisting of: interferons, RNA-dependent RNA polymerase inhibitors (e.g., Remdesivir (Rudexilevir or GS-5734), Favipiravir (favipiravir), Galidesivir, GS-441524); lopinavir (Lopinavir), Ritonavir (Ritonavir), Nelfinavir (Nelfinavir); chloroquine (Chloroquine, Sigma-C6628), hydroxychloroquine (hydroxychloroquine), cyclosporine (cyclosporine), colimycin (carromycin), baicalin (baicain), baicalein (baicalein), Naphthoquine (napthoquine), Ciclesonide (Ciclesonide), Ribavirin (Ribavirin), Penciclovir (Penciclovir), Leflunomide (Leflunomide), Teriflunomide (Teriflunomide), naftifimide (temulomide), nafamostat (nafamostat), nitate (nitazoxanide), Darunavir (Darunavir), Arbidol (Arbidol), Camostat (Camostat), Niclosamide (nicamide), bartinib (barnitinib), rurunavir (raltinib), Saquinavir (Saquinavir), sinavir (quinavir), or a pharmaceutically acceptable salt thereof;
and/or said second active ingredient is selected from the group consisting of: zinc (Zinc), Fingolimod (Fingolimod), vitamin c (vitamin c), Olmesartan Medoxomil (Olmesartan Medoxomil), valsartan (valsartan), Losartan (Losartan), Thalidomide (thiaidomide), glycyrrhizic acid (glycyrrhetic acid), Artemisinin (Artemisinin), dihydroartemisinin (dihydroartesunine), Artesunate (Artesunate), Artemisone (Artemisone), Azithromycin (Azithromycin), Escin (Escin), Naproxen (Naproxen), or combinations thereof;
and (b) a pharmaceutically acceptable carrier.
7. The pharmaceutical composition of claim 6, wherein the pharmaceutical composition is for inhibiting coronavirus PLproAnd (3) protein activity.
8. Use of a pharmaceutical composition according to claim 6 for the preparation of a medicament for (a) inhibiting coronavirus; and/or (b) a medicament for the treatment and/or prevention, amelioration of a related disease caused by a coronavirus infection.
9. Novel coronavirus PL inhibitionproA method of producing a protein, comprising the steps of:
mixing a first active ingredient or a preparation containing the first active ingredient with PL of coronavirus (SARS-CoV-2)proProtein contact, inhibition of said coronavirus PLproThe activity of the protein; or
Contacting a first active ingredient or a formulation comprising said first active ingredient with a coronavirus (SARS-CoV-2) to inhibit said coronavirus PLproActivity of the protein, thereby inhibiting replication of the coronavirus;
wherein the first active ingredient is selected from the group consisting of the compounds of table 1 or pharmaceutically acceptable salts thereof or combinations thereof.
10. The method of claim 9, wherein the first active ingredient is selected from the group consisting of: CD0945-G005, CD0946-B009, CD3226-D010, CD3531-C011, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
CN202010577020.0A 2020-06-22 2020-06-22 247 compounds and their use in combating infection by new coronaviruses Pending CN113893345A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010577020.0A CN113893345A (en) 2020-06-22 2020-06-22 247 compounds and their use in combating infection by new coronaviruses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010577020.0A CN113893345A (en) 2020-06-22 2020-06-22 247 compounds and their use in combating infection by new coronaviruses

Publications (1)

Publication Number Publication Date
CN113893345A true CN113893345A (en) 2022-01-07

Family

ID=79186566

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010577020.0A Pending CN113893345A (en) 2020-06-22 2020-06-22 247 compounds and their use in combating infection by new coronaviruses

Country Status (1)

Country Link
CN (1) CN113893345A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023285654A3 (en) * 2021-07-15 2023-02-16 Dompe' Farmaceutici Spa Compounds for the treatment of covid-19

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023285654A3 (en) * 2021-07-15 2023-02-16 Dompe' Farmaceutici Spa Compounds for the treatment of covid-19

Similar Documents

Publication Publication Date Title
Dos Santos Natural history of COVID-19 and current knowledge on treatment therapeutic options
CN116236580B (en) Application of old medicines such as auranofin and the like and compositions thereof in resisting single positive strand RNA viruses
CN113521289A (en) Application of 15 effective components of medicine in resisting virus infection
CN113244211B (en) Application of baicalein and baicalin in preparing 3CL protease inhibitor of coronavirus SARS-CoV-2
CN113491703B (en) Application of phenylethanoid glycosides compounds and composition thereof in preparation of medicines for preventing and treating new coronavirus infection
WO2021175295A1 (en) Application of myricetin compound in preparation of drugs for prevention and treatment of novel coronavirus pneumonia
CN114796177B (en) Anti-coronavirus medicine and application
CN113262224A (en) Application of nelfinavir in preparing medicine for preventing and treating new coronary pneumonia
CN113679726A (en) Application of salvia miltiorrhiza extract and quinone compounds in resisting coronavirus
El Kantar et al. Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites
CN114699419A (en) Use of a PLpro protein inhibitor in a medicament for the treatment or prevention of a novel coronavirus infection
CN113332363A (en) Application of tea extract and composition thereof in resisting coronavirus
CN113491699A (en) Application of mycophenolic acid or combination preparation containing mycophenolic acid in resisting coronavirus
CN113893345A (en) 247 compounds and their use in combating infection by new coronaviruses
CN113440527B (en) Application of naphthoquine or naphthoquine-containing combined preparation in resisting coronavirus
CN115666572A (en) Pharmaceutical composition for preventing or treating epidemic RNA virus infection
Nomier et al. Distinctive Therapeutic Strategies against Corona Virus19 (COVID-19): A Pharmacological Review.
CN113893347A (en) 1869 application of compound and composition thereof in resisting novel coronavirus infection
CN113952457A (en) Application of termitimide or pharmaceutical composition containing termitimide in resisting coronavirus
US20230233510A1 (en) Cysteine protease inhibitors for use in the prevention and/or treatment of coronavirus
CN115666576A (en) Compound for treating and/or preventing diseases caused by coronavirus and application thereof
CN111568900A (en) Application of indomethacin in resisting coronavirus infection
US10016377B2 (en) Treatment of hepatitis C using histone deacetylase inhibitors
CN114983993B (en) Application of myricetin and dihydromyricetin phosphate compounds in medicines for preventing and treating new coronaries pneumonia
CN113197886A (en) Application of Shuanghuanglian preparation in resisting virus infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220107